Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Zika virus (ZIKV) NS2B-NS3 protease is a heterodimeric enzyme complex essential for the viral life cycle. It consists of the N-terminal domain of the non-structural protein 3 (NS3), which contains the catalytic triad (His51, Asp75, Ser135), and the non-structural protein 2B (NS2B), which acts as an indispensable cofactor for protease activity and membrane anchoring [5, 13]. The primary biological function of this serine protease is to cleave the viral polyprotein precursor into individual functional structural and non-structural proteins, a process required for viral maturation and replication [6, 15]. Beyond its role in replication, the protease also contributes to the evasion of the host's innate immune response by cleaving cellular signaling proteins [1, 5]. Due to its critical role in the pathogenesis of Zika virus infection, including its association with microcephaly and Guillain-Barré syndrome, the NS2B-NS3 protease is a major target for antiviral drug development [3, 9]. Current therapeutic strategies focus on both orthosteric inhibitors that bind the active site and allosteric inhibitors that disrupt the NS2B-NS3 interaction [7, 10]. However, achieving high selectivity over human host proteases and ensuring drug delivery to the central nervous system and developing fetus remain significant challenges [1, 18].
Competitive inhibition of the protease active site (orthosteric) and non-competitive inhibition via the allosteric site to disrupt cofactor-protease interaction.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zika virus non-structural protein 2B-non-structural protein 3 protease (NS2B-NS3) (NS2B-NS3).